REVIVE study: a prospective observational study in chemotherapy after nivolumab therapy for advanced gastric cancer.
暂无分享,去创建一个
T. Yamanaka | K. Muro | T. Nishina | T. Moriwaki | H. Shoji | H. Kawakami | T. Misumi | Y. Sunakawa | Michio Nakamura | Y. Narita | T. Mizukami | S. Kawai
[1] C. Fuchs,et al. O-12 KEYNOTE-061: Response to subsequent therapy following second-line pembrolizumab or paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma , 2020 .
[2] K. Muro,et al. Efficacy of Cytotoxic Agents After Progression on Anti-PD-(L)1 Antibody for Pre-treated Metastatic Gastric Cancer , 2020, AntiCancer Research.
[3] N. Yamamoto,et al. Propensity score–weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non–small cell lung cancer (WJOG10217L) , 2020, Journal for ImmunoTherapy of Cancer.
[4] F. Bidault,et al. Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. , 2019, European journal of cancer.
[5] G. Beretta,et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2018, The Lancet. Oncology.
[6] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[7] E. Van Cutsem,et al. Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300 , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] Sean S. Park,et al. CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy. , 2018, JCI insight.
[9] K. Muro,et al. Salvage chemotherapy with the combination of oxaliplatin, leucovorin, and 5-fluorouracil in advanced gastric cancer refractory or intolerant to fluoropyrimidines, platinum, taxanes, and irinotecan , 2018, Gastric Cancer.
[10] J. Ahn,et al. Increased Response Rates to Salvage Chemotherapy Administered after PD‐1/PD‐L1 Inhibitors in Patients with Non–Small Cell Lung Cancer , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[11] K. Akashi,et al. Irinotecan monotherapy as third-line or later treatment in advanced gastric cancer , 2018, Gastric Cancer.
[12] T. Yoshikawa,et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.
[13] J. Lee,et al. Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer. , 2017, Lung cancer.
[14] T. Nishimura,et al. Irinotecan monotherapy as third-line treatment for advanced gastric cancer refractory to fluoropyrimidines, platinum, and taxanes , 2017, Gastric Cancer.
[15] T. Nakajima,et al. Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody , 2016, Investigational New Drugs.
[16] H. Yasui,et al. Efficacy and safety of irinotecan monotherapy as third-line treatment for advanced gastric cancer , 2016, Cancer Chemotherapy and Pharmacology.
[17] T. Choueiri,et al. Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma. , 2015, European journal of cancer.
[18] L. Emens,et al. The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies , 2015, Cancer Immunology Research.
[19] J. Sosman,et al. Severe Cutaneous and Neurologic Toxicity in Melanoma Patients during Vemurafenib Administration Following Anti-PD-1 Therapy , 2013, Cancer Immunology Research.
[20] J. Wolchok,et al. Hepatotoxicity with combination of vemurafenib and ipilimumab. , 2013, The New England journal of medicine.
[21] N. Boku,et al. Modified FOLFOX-6 therapy for heavily pretreated advanced gastric cancer refractory to fluorouracil, irinotecan, cisplatin and taxanes: a retrospective study. , 2012, Japanese journal of clinical oncology.
[22] J. Harding,et al. Vemurafenib sensitivity skin reaction after ipilimumab. , 2012, The New England journal of medicine.
[23] Israel Lowy,et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Yixiang Wang,et al. Activated CD4+ T Cells Dramatically Enhance Chemotherapeutic Tumor Responses In Vitro and In Vivo , 2009, The Journal of Immunology.
[25] Masahiro Takeuchi,et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. , 2008, The Lancet. Oncology.
[26] J. Heo,et al. Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[27] A. Norman,et al. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] U. Haglund,et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[29] S. Pyrhönen,et al. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. , 1995, British Journal of Cancer.
[30] A. Petroianu,et al. Modified therapy with 5‐fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer , 1993, Cancer.